| Name | Title | Contact Details |
|---|
Cleveland BioLabs, Inc. (NASDAQ: CBLI) is an innovative bio pharmaceutical company developing novel approaches to activate the immune system and address serious medical needs. Our proprietary platform of toll-like immune receptor activators has applications in radiation mitigation, oncology immunotherapy, and vaccines. We combine our proven scientific expertise and our depth of knowledge about our products’ mechanisms of action into a passion for developing drugs to save lives. Our proprietary drug candidates act via unique mechanisms that are designed to kill cancer and protect healthy cells. Our most advanced product candidate is entolimod, which we are developing as a radiation countermeasure and an immunotherapy for oncology and other indications. We have additional pipeline product candidates in various stages of development.
Intrinsic Therapeutics, Inc is a MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ampersand Health is developing markets, opening clinics and implementing proprietary workflows through investment in the most powerful and efficient mechanism for improving health and reducing costs - primary care. Ampersand Health tailors its solutions for health plans operating in inner city markets serving Medicare Advantage, Managed Medicaid and Dual Eligible members.
Saskatchewan Health Research Foundation is a Saskatoon, SK-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT™ Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company's LUMA imaging technology has received FDA approval for an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available in the market today.